@article{21848,
  abstract     = {Despite the success of mRNA therapeutics, challenges remain in optimizing immune responses and minimizing side effects. Cell-specific antigen delivery may help reduce required doses and improve vaccine efficacy. In this study, we report on a targeted delivery system for mRNA to a specific subset of skin-resident antigen-presenting cells: Langerhans cells. By functionalizing lipid nanoparticles with a langerin-specific glycomimetic ligand, we achieve selective mRNA delivery to both murine and human primary Langerhans cells with minimal off-target uptake, at the same time resulting in significantly increased mRNA translation. This targeted mRNA delivery not only enhances antigen presentation and T-cell responses but also enables dose-sparing and superior antitumor immunity compared with conventional immunization in a B16-OVA tumor model. Importantly, our platform’s high compatibility with various lipid nanoparticle formulations offers a flexible and precise tool for skin-directed mRNA delivery.},
  author       = {Klein, Klara and Johnson, Litty and Rîca, Ramona and Sarcevic, Mirza and Carta, Gabriele and Seiser, Saskia and Elbe-Bürger, Adelheid and Langer, Freyja and Rahhal, Nowras and Rademacher, Christoph and Wawrzinek, Robert and Quattrone, Federica and Sparber, Florian},
  issn         = {1523-1747},
  journal      = {Journal of Investigative Dermatology},
  publisher    = {Elsevier},
  title        = {{Langerhans cell–targeted mRNA delivery: A strategy for dose-sparing and enhanced antitumor immunity}},
  doi          = {10.1016/j.jid.2026.03.026},
  year         = {2026},
}